DAY ONE BIOPHARMACEUTICALS I (DAWN) Stock Earnings Estimates
NASDAQ:DAWN • US23954D1090
11.35 USD
+0.35 (+3.18%)
At close: Feb 13, 2026
11.36 USD
+0.01 (+0.09%)
After Hours: 2/13/2026, 8:01:55 PM
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 131.161M | 155.12M 18.27% | 230.19M 48.39% | 320.11M 39.06% | 443.19M 38.45% | 554.19M 25.05% | 665.56M 20.10% | 808.46M 21.47% | 782.66M -3.19% | 846.73M 8.19% | |||
| EBITDA YoY % growth | -146.85M -101.94% | -206.028M -40.30% | -215.708M -4.70% | -119.424M 44.64% | -71.203M 40.38% | -38.994M 45.24% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -146.91M -101.97% | -206.064M -40.27% | -217.27M -5.44% | -127.02M 41.54% | -79.915M 37.08% | 18.991M 123.76% | 114.55M 503.18% | 203.47M 77.63% | 294.78M 44.88% | 379.95M 28.89% | 415.56M 9.37% | 454.96M 9.48% | |
| Operating Margin | N/A | N/A | -165.65% | -81.89% | -34.72% | 5.93% | 25.85% | 36.71% | 44.29% | 47.00% | 53.10% | 53.73% | |
| EPS YoY % growth | -2.17 36.64% | -2.38 -9.68% | -1.78 25.21% | -1.01 43.21% | -0.66 34.45% | 0.01 101.76% | 0.84 7,095.98% | 1.55 84.19% | 2.21 43.07% | 2.76 25.03% | 2.40 -13.28% | 2.60 8.30% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.17 73.44% | -0.30 15.32% | -0.15 48.05% | -0.11 43.33% | -0.07 60.52% |
| Revenue Q2Q % growth | 48.128M 64.82% | 51.378M 67.02% | 56.4M 66.33% | 64.094M 61.06% | 72.567M 50.78% |
| EBITDA Q2Q % growth | -20.255M 68.00% | -31.97M 20.57% | -29.097M 12.54% | -23.794M -9.85% | N/A |
| EBIT Q2Q % growth | -24.033M 63.21% | -18.047M 56.05% | -14.721M 57.91% | -9.235M 61.92% | -437.835K 98.18% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2025 Q2Q % growth | -0.19 48.65% | -0.30 | 0.11 | 36.38% |
| Q2 2025 Q2Q % growth | -0.29 -480.00% | -0.36 | 0.07 | 20.33% |
| Q1 2025 Q2Q % growth | -0.35 51.39% | -0.45 | 0.10 | 22.45% |
| Q4 2024 Q2Q % growth | -0.64 | -0.37 | -0.27 | -73.33% |
| Q3 2024 Q2Q % growth | -0.37 31.48% | -0.42 | 0.05 | 11.53% |
| Q2 2024 Q2Q % growth | -0.05 91.80% | -0.77 | 0.72 | 93.47% |
| Q1 2024 Q2Q % growth | -0.72 -22.03% | -0.68 | -0.04 | -6.41% |
| Q4 2023 Q2Q % growth | -0.64 -14.29% | -0.59 | -0.05 | -7.56% |
| Q3 2023 Q2Q % growth | -0.54 -1.89% | -0.61 | 0.07 | 12.11% |
| Q2 2023 Q2Q % growth | -0.61 -1.67% | -0.62 | 0.01 | 1.98% |
| Q1 2023 Q2Q % growth | -0.59 -22.92% | -0.60 | 0.01 | 2.33% |
| Q4 2022 Q2Q % growth | -0.56 -55.56% | -0.58 | 0.02 | 3.12% |
| Q3 2022 Q2Q % growth | -0.53 -60.61% | -0.54 | 0.01 | 2.70% |
| Q2 2022 Q2Q % growth | -0.60 88.10% | -0.50 | -0.10 | -20.66% |
| Q1 2022 Q2Q % growth | -0.48 | -0.39 | -0.09 | -22.23% |
| Q4 2021 Q2Q % growth | -0.36 | -0.36 | 0.00 | 1.28% |
| Q3 2021 Q2Q % growth | -0.33 | -0.29 | -0.04 | -15.44% |
| Q2 2021 Q2Q % growth | -5.04 | -0.32 | -4.72 | -1,468.63% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2025 Q2Q % growth | 39.795M 98.28% | 38.964M | 831K | 2.13% |
| Q2 2025 Q2Q % growth | 33.908M 313.92% | 36.007M | -2.099M | -5.83% |
| Q1 2025 Q2Q % growth | 30.761M | 30.842M | -81K | -0.26% |
| Q4 2024 Q2Q % growth | 29.2M | 28.348M | 852K | 3.01% |
| Q3 2024 Q2Q % growth | 20.07M | 24.016M | -3.946M | -16.43% |
| Q2 2024 Q2Q % growth | 8.192M | 1.042M | 7.15M | 686.18% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 11.5% | 27.36% | 2.75% | 18.7% |
| Revenue | 2.95% | 8.08% | 0.81% | 4.78% |